SB 202190 (hydrochloride) 是一种选择性 p38 MAP 激酶抑制剂，对 p38α 和 p38β2 的 IC50 分别为 50 nM 和 100 nM。
| Cas No. | 350228-36-3 |
| 化学名 | 4-[4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-phenol, monohydrochloride |
| Canonical SMILES | FC(C=C1)=CC=C1C2=C(C3=CC=NC=C3)NC(C4=CC=C(O)C=C4)=N2.Cl |
| 分子式 | C20H14FN3O.HCl |
| 分子量 | 367.8 |
| 溶解度 | DMF: 30 mg/mL,DMSO: 30 mg/mL,Ethanol: 30 mg/mL,Ethanol:PBS (pH 7.2) (1:10): 0.1 mg/mL |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | SB 202190 is a potent, selective, and cell-permeable inhibitor of p38 MAP kinases, inhibiting p38α (SAPK2A, MAPK14) and p38β (SAPK2B, MAPK11) with IC50 values of 50 and 100 nM, respectively. When tested at 10 μM, SB 202190 has negligible effects on a range of other kinases, including other MAP kinases such as ERK and JNK. It directly binds to the ATP binding pocket of p38 MAP kinases. SB 202190 has been used to elucidate the roles of p38 MAP kinases in inflammatory cytokine expression, nicotine-induced receptor expression, and HIV-mediated depressive disorder. |
m.cnreagent.com